



COQUI RADIOPHARMACEUTICALS

March 15, 2010

Mary Jane Ross Lee
Chief, Office of Nuclear Reactor Regulation
U.S. Nuclear Regulatory Commission
Mail Stop O-12D03
11545 Rockville Pike
Rockville, MD 20852-2738

Subject: Notice of Intent to Submit Applications to License and Operate a Medical Mo99
Production Complex

This letter serves as notification of Coquí Radio Pharmaceuticals Corp. ("Coquí") intent to submit applications to the U.S. Nuclear Regulatory Commission to license and operate a Medical Mo99 Production Complex (MMPC).

We foresee that the License Application will include two non-power, pool type reactors to irradiate low enriched uranium targets, with another license that will include the associated processing plant to produce Molybdenum-99 for use in the medical industry. All the facilities would be located at the site detailed in the enclosed addendum.

Coquí plans to submit combined construction and operating license applications as early as December 2010 with pre-licensing discussions to begin beforehand. This notice is provided to facilitate your resource and budget planning. As part of the pre-licensing discussions and process, Coquí intends to propose solutions to and request NRC disposition of potential policy issues related to the licensing and operation of the facilities that have been identified and are key to the success of the project. These key policy or regulatory issues will be provided to the NRC as early as possible in 2010 for decisions to support project planning.

The details provided in the enclosed addendum for the MMPC have not yet been publicly announced; therefore, Coquí is requesting this information and the accompanying affidavit be withheld from public disclosure as privileged commercial information under 10 CFR 2.390.

Thank you for your attention to this Letter of Intent. If you have any questions, please contact me at 787-993-2800.

Sincerely,

Mark Geurts

COO, Coquí Radio Pharmaceuticals Corp.

5001 A
ADD:
MARYJANE
ROSS-LEE
GLENN
LAPPERT